For the year ending 2025-12-31, TRDA had -$10,817K decrease in cash & cash equivalents over the period. -$129,553K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net (loss) income | -143,750 |
| Depreciation expense | 4,096 |
| Stockbased compensation expense | 19,609 |
| Net amortization of premium (accretion of discount) on marketable securities | 3,671 |
| Collaboration receivable | -2,503 |
| Prepaid expenses and other current assets | -7,642 |
| Right-of-use assets, operating leases | -10,669 |
| Other non-current assets | -214 |
| Accounts payable | -1,799 |
| Accrued expenses and other current liabilities | 4,742 |
| Income taxes payable | -667 |
| Deferred revenue | -19,825 |
| Operating lease liabilities | -8,275 |
| Net cash used in operating activities | -128,512 |
| Purchases of property and equipment | 1,041 |
| Purchases of marketable securities | 141,613 |
| Maturities of marketable securities | 259,462 |
| Net cash provided by (used in) investing activities | 116,808 |
| Proceeds from issuance of common stock and pre-funded warrants in registered direct offering, net of issuance costs paid-Registered Direct Offering | 0 |
| Proceeds from exercise of stock options | 425 |
| Proceeds from issuance of common stock under the employee stock purchase plan | 462 |
| Net cash provided by financing activities | 887 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | -10,817 |
| Cash, cash equivalents and restricted cash at beginning of year | 105,161 |
| Cash, cash equivalents and restricted cash at end of year | 94,344 |
Entrada Therapeutics, Inc. (TRDA)
Entrada Therapeutics, Inc. (TRDA)